{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T02:59:58Z","timestamp":1780541998365,"version":"3.54.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100015310","name":"Natural Science Foundation of Xinjiang","doi-asserted-by":"publisher","award":["2024D01C125"],"award-info":[{"award-number":["2024D01C125"]}],"id":[{"id":"10.13039\/501100015310","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00406-025-02165-y","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T04:19:04Z","timestamp":1770869944000},"page":"1487-1503","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic effects of psilocybin in major depressive disorder: a systematic review and meta-analysis exploring dose effects"],"prefix":"10.1007","volume":"276","author":[{"given":"Ziping","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiemin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junzhe","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuliang","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6877-5193","authenticated-orcid":false,"given":"Jie","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"issue":"1","key":"2165_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41392-024-01738-y","volume":"9","author":"L Cui","year":"2024","unstructured":"Cui L et al (2024) Major depressive disorder: hypothesis, mechanism, prevention and treatment. Signal Transduct Target Ther 9(1):30. https:\/\/doi.org\/10.1038\/s41392-024-01738-y","journal-title":"Signal Transduct Target Ther"},{"key":"2165_CR2","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.Ut17042br1c","author":"MH Trivedi","year":"2020","unstructured":"Trivedi MH (2020) Major depressive disorder in primary care: strategies for identification. J Clin Psychiatry. https:\/\/doi.org\/10.4088\/jcp.Ut17042br1c","journal-title":"J Clin Psychiatry"},{"key":"2165_CR3","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.20m13699","author":"M Zhdanava","year":"2021","unstructured":"Zhdanava M et al (2021) The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States. J Clin Psychiatry. https:\/\/doi.org\/10.4088\/JCP.20m13699","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"2165_CR4","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1176\/appi.ajp.20230025","volume":"180","author":"MK Jha","year":"2023","unstructured":"Jha MK, Mathew SJ (2023) Pharmacotherapies for Treatment-Resistant depression: how antipsychotics fit in the rapidly evolving therapeutic landscape. Am J Psychiatry 180(3):190\u2013199. https:\/\/doi.org\/10.1176\/appi.ajp.20230025","journal-title":"Am J Psychiatry"},{"key":"2165_CR5","doi-asserted-by":"publisher","first-page":"e078084","DOI":"10.1136\/bmj-2023-078084","volume":"385","author":"AM Metaxa","year":"2024","unstructured":"Metaxa AM, Clarke M (2024) Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis. BMJ 385:e078084. https:\/\/doi.org\/10.1136\/bmj-2023-078084","journal-title":"BMJ"},{"issue":"8","key":"2165_CR6","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/da.22532","volume":"33","author":"RC Rossom","year":"2016","unstructured":"Rossom RC et al (2016) Antidepressant adherence across diverse populations and healthcare settings. Depress Anxiety 33(8):765\u2013774. https:\/\/doi.org\/10.1002\/da.22532","journal-title":"Depress Anxiety"},{"issue":"6","key":"2165_CR7","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/bph.15753","volume":"179","author":"\u00c9 Borb\u00e9ly","year":"2022","unstructured":"Borb\u00e9ly \u00c9 et al (2022) Novel drug developmental strategies for treatment-resistant depression. Br J Pharmacol 179(6):1146\u20131186. https:\/\/doi.org\/10.1111\/bph.15753","journal-title":"Br J Pharmacol"},{"issue":"2","key":"2165_CR8","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","volume":"235","author":"RL Carhart-Harris","year":"2018","unstructured":"Carhart-Harris RL et al (2018) Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology 235(2):399\u2013408. https:\/\/doi.org\/10.1007\/s00213-017-4771-x","journal-title":"Psychopharmacology"},{"key":"2165_CR9","doi-asserted-by":"publisher","first-page":"e073823","DOI":"10.1136\/bmj-2022-073823","volume":"386","author":"C Njenga","year":"2024","unstructured":"Njenga C et al (2024) New and emerging treatments for major depressive disorder. BMJ 386:e073823. https:\/\/doi.org\/10.1136\/bmj-2022-073823","journal-title":"BMJ"},{"issue":"6","key":"2165_CR10","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.euroneuro.2018.03.016","volume":"28","author":"O Grimm","year":"2018","unstructured":"Grimm O et al (2018) Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination. Eur Neuropsychopharmacol 28(6):691\u2013700. https:\/\/doi.org\/10.1016\/j.euroneuro.2018.03.016","journal-title":"Eur Neuropsychopharmacol"},{"issue":"4","key":"2165_CR11","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/1355621021000005937","volume":"7","author":"T Passie","year":"2002","unstructured":"Passie T et al (2002) The pharmacology of psilocybin. Addict Biol 7(4):357\u2013364. https:\/\/doi.org\/10.1080\/1355621021000005937","journal-title":"Addict Biol"},{"issue":"1","key":"2165_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40263-021-00877-y","volume":"36","author":"S Ling","year":"2022","unstructured":"Ling S et al (2022) Molecular mechanisms of psilocybin and implications for the treatment of depression. CNS Drugs 36(1):17\u201330. https:\/\/doi.org\/10.1007\/s40263-021-00877-y","journal-title":"CNS Drugs"},{"key":"2165_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26102948","author":"H Lowe","year":"2021","unstructured":"Lowe H et al (2021) The therapeutic potential of psilocybin. Molecules. https:\/\/doi.org\/10.3390\/molecules26102948","journal-title":"Molecules"},{"issue":"9","key":"2165_CR14","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1177\/02698811231190858","volume":"37","author":"P Sharma","year":"2023","unstructured":"Sharma P et al (2023) Psilocybin history, action and reaction: a narrative clinical review. J Psychopharmacol 37(9):849\u2013865. https:\/\/doi.org\/10.1177\/02698811231190858","journal-title":"J Psychopharmacol"},{"issue":"10","key":"2165_CR15","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41429-020-0311-8","volume":"73","author":"DE Nichols","year":"2020","unstructured":"Nichols DE (2020) Psilocybin: from ancient magic to modern medicine. J Antibiot (Tokyo) 73(10):679\u2013686. https:\/\/doi.org\/10.1038\/s41429-020-0311-8","journal-title":"J Antibiot (Tokyo)"},{"key":"2165_CR16","doi-asserted-by":"publisher","first-page":"109504","DOI":"10.1016\/j.neuropharm.2023.109504","volume":"231","author":"AB Wulff","year":"2023","unstructured":"Wulff AB, Nichols CD, Thompson SM (2023) Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders. Neuropharmacology 231:109504. https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109504","journal-title":"Neuropharmacology"},{"issue":"3","key":"2165_CR17","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1007\/s13311-017-0542-y","volume":"14","author":"MW Johnson","year":"2017","unstructured":"Johnson MW, Griffiths RR (2017) Potential therapeutic effects of psilocybin. Neurotherapeutics 14(3):734\u2013740. https:\/\/doi.org\/10.1007\/s13311-017-0542-y","journal-title":"Neurotherapeutics"},{"issue":"9","key":"2165_CR18","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2023.14530","volume":"330","author":"CL Raison","year":"2023","unstructured":"Raison CL et al (2023) Single-Dose psilocybin treatment for major depressive disorder: a randomized clinical trial. JAMA 330(9):843\u2013853. https:\/\/doi.org\/10.1001\/jama.2023.14530","journal-title":"JAMA"},{"issue":"18","key":"2165_CR19","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","volume":"387","author":"GM Goodwin","year":"2022","unstructured":"Goodwin GM et al (2022) Single-Dose psilocybin for a Treatment-Resistant episode of major depression. N Engl J Med 387(18):1637\u20131648. https:\/\/doi.org\/10.1056\/NEJMoa2206443","journal-title":"N Engl J Med"},{"issue":"5","key":"2165_CR20","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","volume":"78","author":"AK Davis","year":"2021","unstructured":"Davis AK et al (2021) Effects of Psilocybin-Assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry 78(5):481\u2013489. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.3285","journal-title":"JAMA Psychiatry"},{"key":"2165_CR21","doi-asserted-by":"publisher","first-page":"1359088","DOI":"10.3389\/fpsyt.2024.1359088","volume":"15","author":"S Fang","year":"2024","unstructured":"Fang S, Yang X, Zhang W (2024) Efficacy and acceptability of psilocybin for primary or secondary depression: a systematic review and meta-analysis of randomized controlled trials. Front Psychiatry 15:1359088. https:\/\/doi.org\/10.3389\/fpsyt.2024.1359088","journal-title":"Front Psychiatry"},{"key":"2165_CR22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jad.2021.09.041","volume":"296","author":"NX Li","year":"2022","unstructured":"Li NX et al (2022) Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis. J Affect Disord 296:26\u201334. https:\/\/doi.org\/10.1016\/j.jad.2021.09.041","journal-title":"J Affect Disord"},{"key":"2165_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11040938","author":"CL Yu","year":"2022","unstructured":"Yu CL et al (2022) Trajectory of antidepressant effects after Single- or Two-Dose administration of psilocybin: a systematic review and multivariate meta-analysis. J Clin Med. https:\/\/doi.org\/10.3390\/jcm11040938","journal-title":"J Clin Med"},{"key":"2165_CR24","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"2165_CR25","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","volume":"134","author":"SA Montgomery","year":"1979","unstructured":"Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382\u2013389. https:\/\/doi.org\/10.1192\/bjp.134.4.382","journal-title":"Br J Psychiatry"},{"issue":"1","key":"2165_CR26","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","volume":"23","author":"M Hamilton","year":"1960","unstructured":"Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23(1):56\u201362. https:\/\/doi.org\/10.1136\/jnnp.23.1.56","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2165_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1411","author":"LA McGuinness","year":"2020","unstructured":"McGuinness LA, Higgins JPT (2020) Risk-of-bias visualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. https:\/\/doi.org\/10.1002\/jrsm.1411. n\/a(n\/a)","journal-title":"Res Synthesis Methods"},{"key":"2165_CR28","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Cumpston J, Li T, Page MJ, Welch VA (eds) (2023) Cochrane handbook for systematic reviews of interventions version 6.5 (updated August 2024). Cochrane"},{"key":"2165_CR29","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"2165_CR30","unstructured":"Team RC (2023) R: A Language and environment for statistical computing. R Foundation for Statistical Computing"},{"issue":"Pt 3","key":"2165_CR31","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1348\/000711010x502733","volume":"63","author":"AP Field","year":"2010","unstructured":"Field AP, Gillett R (2010) How to do a meta-analysis. Br J Math Stat Psychol 63(Pt 3):665\u2013694. https:\/\/doi.org\/10.1348\/000711010x502733","journal-title":"Br J Math Stat Psychol"},{"issue":"7","key":"2165_CR32","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1177\/02698811231154852","volume":"37","author":"J Sloshower","year":"2023","unstructured":"Sloshower J et al (2023) Psilocybin-assisted therapy for major depressive disorder: an exploratory placebo-controlled, fixed-order trial. J Psychopharmacol 37(7):698\u2013706. https:\/\/doi.org\/10.1177\/02698811231154852","journal-title":"J Psychopharmacol"},{"issue":"7","key":"2165_CR33","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/s2215-0366(16)30065-7","volume":"3","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL et al (2016) Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 3(7):619\u2013627. https:\/\/doi.org\/10.1016\/s2215-0366(16)30065-7","journal-title":"Lancet Psychiatry"},{"key":"2165_CR34","doi-asserted-by":"publisher","unstructured":"Aaronson S, Miller T, Rudow S, Forbes M, Shoultz A, Suppes T (2022) An open label pilot of the safety and efficacy of Comp360 psilocybin in patients with severe treatment- resistant depression. Neuropsychopharmacology 47(1):196\u2013197. https:\/\/doi.org\/10.1038\/s41386-022-01484-1","DOI":"10.1038\/s41386-022-01484-1"},{"key":"2165_CR35","doi-asserted-by":"publisher","first-page":"101809","DOI":"10.1016\/j.eclinm.2022.101809","volume":"56","author":"R von Rotz","year":"2023","unstructured":"von Rotz R et al (2023) Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine 56:101809. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101809","journal-title":"EClinicalMedicine"},{"issue":"24","key":"2165_CR36","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1001\/jama.2018.19319","volume":"320","author":"D Gregori","year":"2018","unstructured":"Gregori D et al (2018) Association of Pharmacological treatments with long-term pain control in patients with knee osteoarthritis: a systematic review and Meta-analysis. JAMA 320(24):2564\u20132579. https:\/\/doi.org\/10.1001\/jama.2018.19319","journal-title":"JAMA"},{"key":"2165_CR37","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.euroneuro.2023.07.011","volume":"76","author":"N Perez","year":"2023","unstructured":"Perez N et al (2023) Psilocybin-assisted therapy for depression: a systematic review and dose-response meta-analysis of human studies. Eur Neuropsychopharmacol 76:61\u201376. https:\/\/doi.org\/10.1016\/j.euroneuro.2023.07.011","journal-title":"Eur Neuropsychopharmacol"},{"issue":"12","key":"2165_CR38","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","volume":"30","author":"S Ross","year":"2016","unstructured":"Ross S et al (2016) Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol 30(12):1165\u20131180. https:\/\/doi.org\/10.1177\/0269881116675512","journal-title":"J Psychopharmacol"},{"issue":"12","key":"2165_CR39","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths RR et al (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol 30(12):1181\u20131197. https:\/\/doi.org\/10.1177\/0269881116675513","journal-title":"J Psychopharmacol"},{"issue":"6","key":"2165_CR40","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1001\/jamaoncol.2023.0351","volume":"9","author":"M Agrawal","year":"2023","unstructured":"Agrawal M et al (2023) Assessment of psilocybin therapy for patients with cancer and major depression disorder. JAMA Oncol 9(6):864\u2013866. https:\/\/doi.org\/10.1001\/jamaoncol.2023.0351","journal-title":"JAMA Oncol"},{"key":"2165_CR41","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/7854_2022_366","volume":"56","author":"AJ Khan","year":"2022","unstructured":"Khan AJ et al (2022) Psilocybin for trauma-related disorders. Curr Top Behav Neurosci 56:319\u2013332. https:\/\/doi.org\/10.1007\/7854_2022_366","journal-title":"Curr Top Behav Neurosci"},{"issue":"5","key":"2165_CR42","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1176\/appi.ajp.2019.19010035","volume":"177","author":"CM Reiff","year":"2020","unstructured":"Reiff CM et al (2020) Psychedelics and psychedelic-assisted psychotherapy. Am J Psychiatry 177(5):391\u2013410. https:\/\/doi.org\/10.1176\/appi.ajp.2019.19010035","journal-title":"Am J Psychiatry"},{"key":"2165_CR43","doi-asserted-by":"publisher","first-page":"e078607","DOI":"10.1136\/bmj-2023-078607","volume":"386","author":"TW Hsu","year":"2024","unstructured":"Hsu TW et al (2024) Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and bayesian network meta-analysis. BMJ 386:e078607. https:\/\/doi.org\/10.1136\/bmj-2023-078607","journal-title":"BMJ"},{"key":"2165_CR44","doi-asserted-by":"publisher","unstructured":"Henr\u00edquez-Hern\u00e1ndez LA et al (2023) Hofmann vs. Paracelsus: do psychedelics defy the basics of Toxicology?-a systematic review of the main ergolamines, simple tryptamines, and phenylethylamines. Toxics. https:\/\/doi.org\/10.3390\/toxics11020148","DOI":"10.3390\/toxics11020148"},{"key":"2165_CR45","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.2c10219","author":"J Cui","year":"2023","unstructured":"Cui J et al (2023) Immune exosomes loading Self-Assembled nanomicelles traverse the blood-brain barrier for chemo-immunotherapy against glioblastoma. ACS Nano. https:\/\/doi.org\/10.1021\/acsnano.2c10219","journal-title":"ACS Nano"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-025-02165-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00406-025-02165-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-025-02165-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T02:00:52Z","timestamp":1780538452000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00406-025-02165-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2165"],"URL":"https:\/\/doi.org\/10.1007\/s00406-025-02165-y","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"2 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Data will be made available on request from the corresponding author.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}